Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
Jan Harder(Hegau-Bodensee-Klinikum Singen), Michael Geißler(Klinikum Esslingen), Gabriele Ihorst, Christoph Röcken(Christian-Albrechts-Universität zu Kiel), Volker Heinemann(Comprehensive Cancer Center Vienna), Stefan Boeck(Ludwig-Maximilians-Universität München), Markus Moehler(Inserm), Michael Bitzer(University Children's Hospital Tübingen), Peter Buechler(Heidelberg University), Claudia Schmoor(University Medical Center Freiburg), Esther Endlicher(University Hospital Regensburg), A. Reinacher-Schick(Universitätsklinikum Knappschaftskrankenhaus Bochum), Ralf‐Dieter Hofheinz(Goethe University Frankfurt), Günter Kloeppel(Christian-Albrechts-Universität zu Kiel)
Cited by 184
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k